Personnel Moves Archives - Page 40 of 42

NextPhase Medical Devices appoints new CCO

NextPhase Medical Devices announced today that it appointed Robert Olsen to its newly created role of chief commercial officer.

Olsen’s responsibilities within the role include commercialization, leading sales, marketing and value streams, overseeing revenue and profit growth and ensuring customer satisfaction for the Waldwick, N.J.-based medical device contract manufacturer, according to a news release.

A veteran of more than 30 years in the medical device contract manufacturing space, Olsen has spent the past three years with NextPhase Medical Devices, having previously served as senior VP of business development. He also held sales, business development and leadership roles at companies such as Vention Medical, Flex and Nypro.

“We are fortunate to have a leader with Rob’s industry experience and passion for excellence,” NextPhase Medical Devices president & CEO Carlo Colesanti said in the release.“Over the last 3 years, he has been a great s…

Bardy Diagnostics names new CEO

BardyDx Carnation Ambulatory Monitor (CAM™) – P-wave centric™ ambulatory cardiac patch monitoring and arrhythmia detection

Bardy Diagnostics announced that it appointed Kevin Hykes as its new president, CEO and member of its board effective Aug. 31, 2020.

Hykes has more than 28 years of experience in the medical device industry, having served as president and CEO of Relievant Medical Systems, Metavention and Cameron Health. Additionally, Hykes held roles as an operating partner at Revival Healthcare Capital and Versant Ventures, having previously held leadership positions at Medtronic, too.

His role includes responsibilities for leading the development and execution of short-term and long-term business and financial strategies while managing the overall operations of Bardy, according to a news release.

“I’m very excited and pleased to have Kevin join our executive team as Pr…

Titan Medical CFO retires; succesor named

Titan Medical (TSX:TMD;OTC:TITFX) announced today that CFO Stephen Randall will retire and Monique Delorme will assume the role.

Randall has spent more than 10 years with Titan Medical, leading the company through 30 capital transactions and raising more than $260 million to fund research and development for its surgical robotic technologies, according to a news release.

“For the past 10 years, Stephen has played a pivotal role in Titan’s journey from an early-stage startup to become a leader in single-port robotic surgical technologies,” Titan Medical CEO David McNally said in the release. “Stephen’s leadership, guidance and unwavering commitment to Titan has been vital to our business – and for that we thank him.

“I am also pleased that Stephen will remain with the company in his capacity as a director of the board and will continue to guide the company toward realizing its vision for improving patient outcomes with its single-port robotic …

LensGen closes $10 million in bridge financing

LensGen’s Juvene IOL (Image from LensGen)

Intraocular lens developer LensGen announced today that it closed the addition of $10 million in a $20 million bridge financing.

HOYA Group’s corporate investment arm led the financing, which is part of a larger Series B round planned for early 2021 that is earmarked for funding the company through the approval of a pivotal FDA study for its Juvene fluid-optic intraocular lens (IOL) for cataract and presbyopia treatment, according to a news release.

“We are delighted to attract additional investment from an experienced ophthalmology and corporate strategic investor like HOYA in order to advance into the pivotal stage of our FDA clinical study and bring to market an innovative and elegant solution for treating cataracts and presbyopia,” LensGen founder & CEO Ramgopal Rao said in the release.

Irvine, Calif.-based LensGen also a…

BD names IR director

Becton Dickinson (NYSE:BDX) announced yesterday that it appointed Kristen Stewart as its new senior VP of strategy and investor relations.

In the newly created position, Stewart is slated to work closely with the BD executive team to “drive shareholder value and communicate the company’s long-term growth strategy,” according to a news release.

Stewart previously held roles at multiple Wall Street investment banks over two decades, most recently leading the medical technology research franchise at Barclays Capital. Institutional Investor has named her as one of the top three analysts in the medical supplies & devices category several times, BD said.

“I have watched through the analyst lens as BD has transformed into a global medical technology innovator,” Stewart said in the release. “I am excited by BD’s current strategic direction and believe the company has significant potential to optimize shareholder valu…

Centinel Spine appoints new chief financial officer

Centinel Spine this week said it appointed Varun Gandhi as chief financial officer, effective August 17.

Gandhi succeeds Jeff Stello, who had served as interim chief financial officer since late 2018.

Prior to his appointment, Gandhi served as senior VP of corporate finance and strategic planning and GM of international at Centinel Spine. He previously served as VP of strategic planning and corporate finance at Small Bone Innovations, which was later acquired by Stryker.

“Varun Gandhi is a proven financial, strategic, and organizational leader in the orthopedics industry who has made particularly important contributions to Centinel Spine and its growth over the past several years. He knows our company and the spine market deeply. We look forward to Varun’s contributions to the next phase of growth for Centinel Spine,” CEO Steve Murray said in a news release.

Aerin Medical closes $48M financing, appoints new CEO

Aerin Medical announced today that it closed a $48 million equity financing and appointed Matt Brokaw as its new president & CEO.

Brokaw previously served in roles at Tusker Medical, Spirox, Entellus Medical, Stryker (NYSE:SYK), Acclarent, Johnson & Johnson (NYSE:JNJ) and Smith & Nephew (NYSE:SNN).

“Aerin is primed for its next phase of growth, propelled by non-invasive treatments embraced by patients, and in-office procedure options that are increasingly important to the ENT specialty,” Brokaw said in a news release. “I’m tremendously excited to join the team at this critical period, and I look forward to working in close partnership with the otolaryngology community and this experienced group of healthcare investors.”

New investor Questa Capital led the $48 million funding round, while OrbiMed and existing investor KCK Group also participated in the financing, according to the release.

Sunnvale, Calif.-based Aerin, a developer of tre…

Conformis names new marketing VP

Joint replacement implant maker Conformis (NSDQ:CFMS) announced that it appointed Farzin Kaghani as its new VP of U.S. marketing.

Khaghani, a veteran of more than 20 years in orthopedic and medtech sales and marketing, most recently served as president at NextStep Arthropedix, but before that, he spent more than 10 years at Conformis in a number of roles.

According to a news release, Khaghani also served as product director at Johnson & Johnson (NYSE:JNJ) unit DePuy Synthes for five years. Before that, he served as director of operations at Win Enterprises.

“We are very pleased to announce that Farzin Khaghani has rejoined our team as VP, U.S. marketing,” Conformis president & CEO Mark Augusti said in the release. “Farzin’s product expertise and track record of successfully supporting strategic goals and attracting new surgeon users to the Conformis family will help us continue our successful market expansion. I look forward to the co…

TransEnterix appoints CFO

Robotic surgery company TransEnterix (NYSE: TRXC) announced today that it has hired Shameze Rampertab as its news EVP and CFO.

“We are delighted to welcome Shameze to our team during this important time in TransEnterix’s journey,” TransEnterix CEo Anthony Fernando said in a news release. “His extensive experience at implementing financial strategies and sourcing equity and debt financing options will be invaluable as we continue towards our goals for 2020 and beyond. I am confident Shameze will make an immediate positive impact on the organization and help lead TransEnterix through its next phase of growth.”

Rampertab has over 20 years of financial leadership experience in the healthcare sector. He also spent time as an investment banker and sell-side equity research analyst. Most recently, he rose up to become interim CEO at animal health company Zomedica Pharmaceuticals.

TransEnterix recently reported tough but better-than-expected results for its seco…

Irish medtech startup AventaMed brings on U.S.-based CEO

Traditional ear tube surgery alternative developer AventaMed announced that it appointed U.S.-based Keith Jensen as its new president & CEO.

The Cork, Ireland-based medtech startup said in a news release that Jensen will succeed co-founder Olive O’Driscoll in the positions as he attempts to lead the company beyond its current startup phase and into the growth and commercialization phase, having already secured more than $6.2 million (€5.2 million) in funding.

Jensen previously held leadership roles at Boston Scientific, Cortek, InaVein and was president & CEO of Vascular Insights before his most recent position as senior VP of international business for the American Heart Association. O’Driscoll is set to assume an advisory consulting position and remain on the company’s board.

AventaMed develops the Solo Tympanostomy Tube Device (Solo TTD) for the quick and simple insertion of ear tubes without general…

Silk Road Medical appoints chief commercial officer

Stroke treatment developer Silk Road Medical (NSDQ:SILK) announced that it promoted Andrew Davis as its new chief commercial officer.

In the newly created role at the Sunnyvale, Calif.-based company, Davis is slated to oversee Silk Road Medical’s global commercialization efforts by establishing near-term priorities and setting the long-term strategic direction for the organization, according to a news release.

“Andy and his team have had a monumental role in our commercial success driving the safe adoption of [transcarotid artery revascularization] across the U.S.,” Silk Road Medical CEO Erica Rogers said in the release. “His contributions to the development of our sales team and commercial strategy have been vital to our organization. In his new role, we are confident that Andy will provide additional strategic direction and value and deliver meaningful and lasting results for Silk Road Medical.”

Davis joined the company as its first commercial le…

Eko names Humbarger as new SVP

Eko announced yesterday that it appointed Bryan Humbarger as its new senior vice president of commercial with an emphasis on sales.

The digital health sales veteran’s new role includes responsibilities for overseeing sales and commercial operations for Eko’s AI and telemedicine software platforms for health systems, practices and providers worldwide, according to a news release.

“Eko’s next generation of cardiac and pulmonary solutions are already making a difference for providers and their patients, and I am thrilled to bring my experience in cardiology and digital health to further accelerate the adoption of Eko’s technology,” Humbarger said in the release. “Being at the forefront of delivering what’s next in cardiovascular care is my passion, and I am thrilled to continue this journey at Eko, a company making a difference in how cardiac and pulmonary care is delivered.”

Oakland, Calif.-based Eko welcomes Humbarger on the back of FDA cleara…